HCW9206 based cell therapy / Wugen, HCW Biologics - LARVOL DELTA

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances (GlobeNewswire) - "The study results demonstrated that HCW9206...provides a revolutionary approach to generate chimeric T-cell receptor - T cells ('CAR-Ts') for immunotherapy with increased function in a cost-effective manner....Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer. In experimental models, human CAR-T cells manufactured using HCW9206 showed strong anti-tumor activity in leukemia and enhanced antiviral potency in HIV suggesting potential for curative outcomes."

Preclinical • Leukemia

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization (GlobeNewswire) - "HCW Biologics Inc....announced today presentation of studies showing that its proprietary fusion protein, HCW9206, provides a new pathway for generating chimeric T-cell receptor - T cells (CAR-Ts) for immunotherapy with increased function....The activity of HCW9206 was significantly superior compared to standard methods employing anti-CD3/anti-CD28 and IL-2 reagents for CAR lentiviral transduction and subsequent expansion and persistence of human CAR-Ts....The poster presentation reported that HCW9206 is not only a better reagent than the current anti-CD3/anti-CD28/IL-2 method for CAR-T viral transduction, it also effectively expanded stem cell-like memory T cells (Tscm) carrying the CAR constructs. It is well established that the Tscm subset of T cells exhibits more in vivo persistence and targeted cell killing than other subsets of T cells, including memory T cells, following adoptive transfer into patients."

Preclinical • Hematological Malignancies

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) - "Business Highlights...Going forward, the Company retains ownership and control of the TOBI platform and TOBI-based molecules, with no restrictions under the Settlement Agreement on its ability to use the TOBI platform for protein-fusion molecules for non-oncology indications. The Company may pursue the clinical development of treatments for cancer indications based on HCW9302, HCW9206 and HCW9201. Further, HCW Biologics retains ownership of the Wugen license and shares of Wugen common stock transferred to the Company as the upfront licensing fee from Wugen for granting the Wugen license...R&D expenses for the quarter ended June 30, 2023 and 2024 were $1.6 million and $2.0 million, respectively...Manufacturing costs increased in three- and six-month periods ended June 30, 2024 because the Company was replenishing its supply of a high-expressing cell line of HCW9101."

Commercial • Licensing / partnership • Hematological Malignancies • Immunology • Oncology • Solid Tumor